Another use for Avastin… blebs!

Article

Bevacizumab (Avastin) may have an application as an adjunct to antifibrosis therapy, according to study results published in the October/November issue of the Journal of Glaucoma.

Bevacizumab (Avastin) may have an application as an adjunct to antifibrosis therapy, according to study results published in the October/November issue of the Journal of Glaucoma.

Michael A. Coote, MBBS, FRANZCO of the University of Melbourne, Australia and colleagues administered a subconjunctival injection of bevacizumab to a bleb. The team monitored bleb vascularity and measured any longitudinal changes that occurred in the six months prior to, and for the six months following, the bevacizumab injection.

Three months after one eye underwent trabeculectomy, cataract surgery was required; 10 days postoperatively, increased scarring activity was correlated to bleb vascularity. The researchers found that the single subconjunctival injection of bevacizumab was associated with a significant reduction in bleb vascularity for six weeks and, at six months, with additional continued steroid therapy, the bleb functioned well, had minimal scar tissue and was healthy and diffuse.

Because the bleb responded so well to the bevacizumab injection, the researchers concluded that this treatment may provide an effective adjunct to antifibrosis therapy, although further studies into bevacizumab’s effect on bleb scarring activity are required.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
© 2025 MJH Life Sciences

All rights reserved.